A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease

Figure 5 ANG3070 attenuates hepatic lesions, fibrosis and improves liver function in the PCK rat. A: Compared to the WT cohort, multiple, highly dilated bile ducts (arrows) are visible in H and E-stained PCK [vehicle (Veh)] livers by week 14; B: Representative Picrosirius red-stained liver showing ductal fibrosis (arrows) in the PCK (Veh) cohort; C-F: At sacrifice, PCK rats (Veh) exhibited increased liver mass (C), liver-to-body mass ratio (D) and aspartate aminotransferase (AST) (E) compared to the WT cohort. Total liver hydroxyproline content was also increased in the PCK rat (F). Treatment with ANG3070 was associated with a reduction in AST (E), hepatic lesions and fibrosis (HYP: Collagen marker) (A, B, C and F) (^bP < 0.01, vs WT; ^dP < 0.01, vs PCK + Veh).